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Abstract
Background: The identification of patients for targeted antineoplastic therapies requires accurate measurement of
therapeutic targets and associated signaling complexes. HER3 signaling through heterodimerization is an important
growth-promoting mechanism in several tumor types and may be a principal resistance mechanism by which EGFR and
HER2 expressing tumors elude targeted therapies. Current methods that can study these interactions are inadequate for
formalin-fixed, paraffin-embedded (FFPE) tumor samples.
Methodology and Principal Findings: Herein, we describe a panel of proximity-directed assays capable of measuring
protein-interactions and phosphorylation in FFPE samples in the HER3/PI3K/Akt pathway and examine the capability of
these assays to inform on the functional state of the pathway. We used FFPE breast cancer cell line and tumor models for
this study. In breast cancer cell lines we observe both ligand-dependent and independent activation of the pathway and
strong correlations between measured activation of key analytes. When selected cell lines are treated with HER2 inhibitors,
we not only observe the expected molecular effects based on mechanism of action knowledge, but also novel effects of
HER2 inhibition on key targets in the HER receptor pathway. Significantly, in a xenograft model of delayed tumor fixation,
HER3 phosphorylation is unstable, while alternate measures of pathway activation, such as formation of the HER3PI3K
complex is preserved. Measurements in breast tumor samples showed correlations between HER3 phosphorylation and
receptor interactions, obviating the need to use phosphorylation as a surrogate for HER3 activation.
Significance: This assay system is capable of quantitatively measuring therapeutically relevant responses and enables
molecular profiling of receptor networks in both preclinical and tumor models.
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Introduction
A goal of modern molecular cancer diagnostics is to identify
the underlying molecular signature of cancers on a patient-by-
patient basis to guide the selection of an appropriate therapeutic
regimen [1]. The capability to measure individual proteins,
protein trafficking and localization, protein-protein interactions
and protein phosphorylation are key requisites to deduce
pathway activation and correlate specific signaling events with
biological outcomes such as cell growth and survival or
resistance/sensitivity to therapeutic treatments [2]. Obtaining
such measurements from formalin-fixed, paraffin-embedded
(FFPE) samples is necessary since patient biopsies are routinely
preserved in this format for histological assessment: unfortunate-
ly, biochemical techniques suitable for this sample type are
severely limited. Measurement of protein expression and protein
phosphorylation by immunohistochemistry is valuable, but
reveals only a partial picture of the signaling network [3] and
is limited by the availability of phosphorylation site-specific
antibodies and lability of certain phosphorylation sites reviewed
in [4]. The measurement of protein-protein interactions is
routine from cell or tissue lysates using standard techniques such
as co-immunoprecipitation and Western blotting, but few
techniques are available for FFPE samples. Besides the approach
described in this publication, to our knowledge the only other
assays capable of measuring protein complexes in FFPE tissue
sections are Fluorescence Resonance Energy Transfer [5] and in
situ proximity ligation assay [6,7].
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for normal cellular development [8–10]; however, several proteins
that mediate ErbB signaling contribute to tumorigenesis in rodents
and humans [11,12]. The ErbB family is comprised of four
members: EGFR/ErbB1/HER1, ErbB2/NeuHER2/, ErbB3/
HER3 and ErbB4/HER4 [9]. Both ligand-induced and ligand-
independent dimerization and activation of HER receptors are
known to occur [9], including formation of the HER2-HER3
heterodimer in HER2 amplified cells [13]. Dimerization is followed
by receptor transactivation and phosphorylation, the recruitment of
various cytosolic proteins to the phosphorylated receptors, thereby
triggering varioussignaling cascades including the PI3K/Akt, PKC,
MAPK and the Ras signaling pathways [14–18].
The measurement of biomarker expression levels has been
successfully employed for selecting patients for monoclonal
antibody-based targeted therapy, as in the treatment with
trastuzumab (anti-HER2 humanized antibody) for HER2 overex-
pressing breast cancer [19,20]. However, even the measurement of
HER2 expression levels has low positive predictive value: the
objective response rate for patients selected for trastuzumab
therapy is less than 35% [21,22]. Utilization of alternate signaling
pathways, in particular, heterodimerization of HER family
members, is often responsible for de novo and acquired resistance
to HER-targeted therapies [22,23]. Dimerization of HER3 with
HER2 is known to be one of the most mitogenic protein
complexes [24] and is frequently implicated as a potential drug
resistance mechanism [25,26]. Conversely, HER3 has also been
identified as a potential marker of drug sensitivity. A phase II study
of lapatinib in HER2-positive inflammatory breast cancer showed
that, phosphorylated HER3 predicted response to lapatinib and
tumors coexpressing phosphorylated HER2 and HER3P were
more likely to respond [27]. As a prognostic marker, expression of
HER3 has been associated with reduced survival in melanoma,
gastric and breast cancer [28,29], although a more complete
picture of the role of HER3 in this regard is yet to emerge. As an
addition to measuring the total HER3 protein, the capability to
measure HER3-phosphatidylinositol-3 kinase (HER3PI3K) path-
way activation could enhance the predictive and prognostic value
of measurement in this pathway. The ability to measure HER3
activation has become more critical as HER3-targeted therapies
are showing promising results in pre-clinical studies [30].
A previous study demonstrating the use of VeraTag
TM
technology in proteomics research reported on the development
of receptor expression and homodimerization assays [31]. In this
report, we describe the development of a panel of proximity-
directed assays to measure protein interactions and protein
phosphorylation in the HER3PI3K pathway using FFPE samples.
We investigate the utility of these assays in measuring clinical
responses in breast cancer cell-lines and in the molecular
characterization of human breast cancer tumors. In summary,
our findings demonstrate a number of viable assays measuring
HER3-complex formation that are useful for assessing HER3
activity in patient tumor samples.
Materials and Methods
Ethics statement
Ethics committee approval of the study was not sought since no
human or animal experiment was performed by the authors. Mouse
tumor xenografts and human tumor FFPE blocks were purchased
from commercial vendors (Charles River Laboratories and
Asterand respectively). The humane care and use of laboratory
animal policy of CRL can be found at http://info.criver.com/
about_charles_river/humane_care_initiative/index.html. The bio-
ethics and privacy policy for Asterand can be found at http://www.
asterand.com/Asterand/about/ethics.htm.
VeraTag assays
Cancer cell-lines and tumors were analyzed in VeraTag assays
to determine HER2-HER3 heterodimers (HER23D), pan HER3
phosphorylation (HER3P), HER3PI3K, Akt serine 473 phosphor-
ylation (pAkt) and total Akt (tAkt).
Cell culture and treatment
All cell-lines were purchased from ATCC. Cells were grown to
confluence and were serum starved overnight prior to heregulin
(HRG) stimulation. Cells were treated with either 200 nM 2C4
(murine pertuzumab, ATCC), 200 nM trastuzumab (Myoderm),
1 mM lapatinib (LC Laboratories) or left untreated for 2 h. HRG
stimulation (60 nM) was done after drug treatment prior to lysis or
fixation and FFPE block preparation. Non-stimulated cells were
lysed or fixed directly after drug treatment.
FFPE assays
FFPE blocks, antibody conjugates and molecular scissors were
prepared for the analyses as detailed in supporting information
(Text S1) and in previous reports [31,32]. The principle of the
VeraTag assay is described in Figure 1. The general assay protocol
is represented by the schematic in Figure S1. The workflow of the
assay is depicted in Figure S2. Antigen retrieval was performed on
the dewaxed and hydrated sections on positively charged glass
slides in Tris buffer (DAKO) in a pressure cooker (Biocare
Medical) following their protocols. Assays were performed with the
following antibodies: HER3P, biotinylated HER3 antibody
(mouse monoclonal, B9A11; Monogram) and VeraTag-labeled
generic p-tyrosine antibody (PT100; CST), HER3PI3K, biotin-
labeled B9A11 and a VeraTag-labeled antibody to the alpha
isoform of the p85 subunit (05-212; Millipore), HER23D, biotin-
labeled B9A11 and VeraTag-labeled HER2 antibody (Ab-8;
Labvision). For the tAkt-pAkt duplex assay, a specific VeraTag
labeled pAkt antibody (4051; CST) was used in combination with
a biotin-labeled Akt1 antibody (SC-1619; Santa Cruz) and a
VeraTag labeled Akt antibody (SC-5298; Santa Cruz). For the
paired isotype control (ITC) experiments, the biotin-labeled
antibody was replaced by a biotin-labeled mouse IgG1 (BD
Biosciences), while all other assay conditions remained the same.
After antibody incubation, streptavidin-methylene blue (SA-MB)
was added to the tissue section followed by photo-cleavage to
release VeraTags, which were separated by capillary electropho-
resis (CE) and quantitated. The details of assay characterization
are provided in Text S1. In general each assay has a high level of
specificity and precision (Figure S3, Figure S4 and Figure S5).
Generation and preparation of N87 xenografts
N87 xenografts (Charles River Laboratories) were generated
following an established protocol. Briefly, 30 mg to 70 mg tumor
fragments from N87 xenografts were implanted into nude mice (3
per group). Tumors were excised from each animal and half of the
tumor was placed into fixative for block-making. Tumor powders
prepared from the remaining half were placed in liquid nitrogen.
The powders were thawed in lysis buffer [1% Triton X-100,
50 mM Tris-HCl (pH 7.5), 35 mM NaCl, 50 mM NaF, 50 mM
sodium beta-glycerophosphate, 1 mM Na3VO4, 5 mM EDTA
and 1 tablet (per 10 ml) complete protease inhibitor (Roche) in de-
ionized water] before protein estimation and SDS-PAGE. Tumors
from mice of group 1 (G1) were frozen or fixed immediately. Mice
from group 2 (G2) were prepared such that 15 min elapsed from
HER3/PI3K Pathway Profiling in Breast Tumors
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from group 3 (G3) were prepared with 30 min elapsing, also at
room temperature until processing. Mice from group 4 (G4) were
prepared with 30 min elapsing but at 4uC. Mice from group 5 (G5)
were prepared with 120 min elapsing at room temperature.
SDS-PAGE and Western blot analysis
For HER3 immunoprecipitation, rabbit polyclonal antibody
SC-285 (Santa Cruz) was incubated with protein G beads (Pierce)
in 100 mM HEPES (pH 8.2), 150 mM NaCl buffer at 4uC for
2 h. The beads were washed and 300 mg of lysate protein was
immunoprecipitated overnight at 4uC with 20 mL antibody-
protein G beads. After immunoprecipitation, the beads were
washed twice with lysis buffer. SDS-sample buffer containing an
additional 50 mM dithiothreitol was added to each precipitate,
and the samples were boiled for 4 min. The samples were run on a
4–12% bis-tris gel and transferred to a PVDF membrane. Co-
immunoprecipitating HER2, p85 and phosphoproteins were
analyzed by Western blot with Ab-8, 05-212 or 4G10 antibodies
respectively. Western blotting for Akt and phospho-Akt proteins
was performed using SC-5298 (Santa Cruz) and 4051 (CST)
antibodies respectively.
Estimation of tumor area
All slides underwent haematoxylin and eosin (H&E) staining after
the completion of VeraTag assays followed by estimation of the
tumor area by a certified pathologist. To the extent possible, tumor
area measurement was restricted to regions of invasive carcinoma
only. Samples with significant necrosis, insignificant tumor content
or ductal carcinoma in situ were excluded from analysis.
Statistical Analysis
Pearson correlation coefficients (r) were used to determine
correlations between the measured targets and a two-tailed p-value
less than 0.03 was considered to represent a statistically significant
correlation. The significance of assay measurements between
untreated and treated samples was assessed by Student’s t test.
Error bars denote the SEM for three measurements unless noted
otherwise.
Results
Measurement of ligand-induced changes in HER23D,
HER3P, HER3PI3K, tAkt and pAkt in cell-lines in FFPE
format
Figures 1A–D depict the FFPE assays for heterodimer,
phosphoprotein and protein-complex measurements used in this
study. A panel of breast cancer cell-lines was selected for
coexpression of a range of HER2 and HER3 receptors (Table
S1). As expected, HRG strongly activated the HER3/PI3K/Akt
pathway in these breast cancer cell-lines [33]. Ligand stimulation
resulted in a 5-fold increase in HER23D, 15-fold increase in
HER3P, 10-fold increase in HER3PI3K complex and 5-fold
increase in the ratio of phospho-to-total Akt (pAkt/tAkt) levels in
MCF7 cells (Figures 2A–D). The total HER2, HER3 and Akt
protein levels remain relatively unchanged (Figure S6). The cells
with highest levels of HER2 had high basal levels of HER23D
(SKBR3), whereas the low HER2 cell-lines (T47D, MCF7) had
low basal HER23D and showed the highest fold-change
inductions with HRG. The ligand-independent dimer is an active
species consistent with the phosphorylation of the downstream
Figure 1. Schematic representation of the VeraTag assays. A pair of antibodies, one of which is conjugated to biotin (B) and the other a
fluorescent molecule suitable for analysis by CE (VeraTag; V), bind to distinct epitopes on a protein or a protein complex. The VeraTag molecules are
attached to the antibodies via photo-cleavable linkers. Each target measured in the assay is assigned to a unique VeraTag. Methylene blue,
conjugated to streptavidin, binds to the biotin-labeled antibody and is photo-activated by red light. The released singlet oxygen, as a result of
methylene blue catalyzed photosensitization, cleaves VeraTag molecules in close proximity to the antibody-biotin-streptavidin complex. (A) HER2-
HER3 heterodimers are measured using HER2- and HER3-specific antibodies. (B) Total HER3 phosphorylation is measured using a HER3-specific and a
generic phosphotyrosine antibody. (C) Interaction of PI3K and HER3 is measured using a HER3-specific antibody and an antibody directed to the p85
component of the PI3K protein. (D) Two distinct VeraTag molecules that can be separated by CE are used in the Akt assay, one for pAkt and the other
for tAkt. Total- and phospho-Akt are measured using a pair of antibodies directed to Akt and a third VeraTag labeled antibody to a specific phospho-
site on Akt.
doi:10.1371/journal.pone.0016443.g001
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HER23D and HER2T signals as measured by the VeraTag
FFPE assays are well correlated and the same pattern is observed
in data from VeraTag lysate assays (Figure S7).
As part of the cross-validation of the VeraTag assay system, we
compared results obtained from FFPE assays to those from
conventional formats like co-immunoprecipitation followed by
SDS-PAGE and Western blotting. Figure 2 shows receptor
complexation and phosphorylation by co-immunoprecipitation/
Westernblotting in the same panel of breastcancer cell-lines used in
the VeraTag FFPE assays and there is generally good correlation
between the cell lysate and FFPE measurements. In cell-lines with
high HER2 expression the ligand-independent dimers constitute a
significant proportion of the dimer signal. Additionally, in high
HER2 cell lines HRG expression is low [34] suggesting that the
presence of HER23 heterodimers is ligand-independent.
VeraTag assay in breast tumor samples
Activation of the HER3/PI3K/Akt pathway in breast tumors
has often been implicated in resistance to HER2-targeted
therapies. We screened a set of 27 breast tumors to determine
our ability to measure HER23D, HER3P and HER3PI3K in
Figure 2. HER2-HER3 heterodimer, phospho-HER3, HER3-PI3K, phospho-Akt analysis of breast cancer cell-lines. The indicated breast
cancer cell-lines with and without HRG stimulation were used in VeraTag FFPE assays. Data from HER23D (A), HER3P (B), HER3PI3K (C) and Akt (D)
FFPE assays were analyzed and the results are plotted in the graphs and the corresponding co-IP WB (A–C) and pAkt western (D) were performed on
the same cell lysate for comparison. The normalized RPA values are plotted on the y-axis. pAkt data is plotted as a function of tAkt. HRG-stimulated
signal is denoted by the solid bars and unstimulated signal by hatch-marked bars. Western lanes are as follows: 1- MB231, 2-MCF7, 3-MCF7_H, 4-
T47D, 5-T47D_H, 6-MB453, 7-MB453_H, 8-SKBR3, 9-SKBR3_H, 10- NIH3T3. Underscore H (_H) indicates cells were treated with HRG.
doi:10.1371/journal.pone.0016443.g002
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clinical setting (Figure 3A). We used cell-line controls to span the
dynamic range of the measurements, allowing for normalization of
the data across multiple batches and ensuring our ability to
compare different batches. The HER23D measurement showed a
dynamic range of greater than 2 logs, while both the HER3P and
the HER3PI3K assays had dynamic range of 1.5 logs. We
excluded from analysis tumors that showed specific signal less than
two-fold of the ITC background (negative). By this criterion, 22 of
the tumors were deemed positive by VeraTag HER3PI3K assay,
while 18 of these tumors showed HER3 activation as measured by
phosphorylation of HER3.
Correlations between protein expression, dimerization
and phosphorylation levels
As observed in cell-lines, the HER23D levels track strongly with
the levels of HER2 in these tumors (p-value,0.0001). Addition-
ally, the HER3P assay shows a statistically significant association
with HER23D (correlation coefficient r of 0.65, p-value =0.0026)
and the HER3PI3K measurement trends with HER23D mea-
surements (r=0.36), although does not reach statistical signifi-
cance in this set of tumors. HER3PI3K and HER3P measure-
ments (Figure 3B) show good correlation (r=0.57, p-value=0.01).
HER2T measurements (Figure 3C) also co-vary with both HER3P
and HER3PI3K measurements (p-value,0.03). There is a trend
for association between HER3T and HER23D measurements (p-
value=0.078) but not between HER3T and HER3PI3K, or
HER3T and HER2T (p-values.0.15). These correlations are
presented in Table 1.
Modulation of the HER2/HER3 pathway with targeted
therapies
In order to measure the inhibition of HER2 mediated HER3
activation, we tested three drugs that target HER2 (2C4,
trastuzumab and lapatinib) using FFPE cell-lines as our model
system. When low HER2-expressing T47D cells are exposed to
the inhibitors followed by ligand stimulation, relative to non-drug
treated control, HER23D is downregulated by 2C4 (,7-fold, p-
value=0.00014) and to a lesser extent by lapatinib, but not by
trastuzumab (Figure 4). Trastuzumab is unable to block the ligand-
induced increases in HER3P, HER3PI3K and pAkt/tAkt either.
Lapatinib downregulated HER3P (,6-fold) and HER3PI3K, in a
manner similar to 2C4. The inhibitors had negligible effect on
pAkt/tAkt in HRG-stimulated T47D cells. The levels of total
HER2, HER3, PI3K, and Akt are relatively unchanged (data not
shown).
As expected, 2C4 is not able to downregulate HER23D in cells
expressing basal levels of this heterodimer, as in BT474 (Figure 5).
In fact, 2C4 does not have a significant inhibitory effect on any
target measured in BT474 except for a small change in pAkt/
tAkt. Trastuzumab, however, blocks basal activation of this
pathway as evidenced by the downregulation of both HER3PI3K
and pAkt/tAkt in BT474 (p-values ,0.006). There is a
downward trend on HER3P, but we detected no measurable
effect of trastuzumab on HER23D. Lapatinib inhibits all four
targets to varying degrees, with the strongest effect (,5-fold) on
pAkt/tAkt (p-value=0.0014) in BT474. The cross-validation of
the FFPE assay data for both the cell-lines is presented in Figure
S8 and Figure S9.
Measurement of HER3 activation in xenografts
We used the N87 gastric cancer xenograft model and the suite
of HER3-related VeraTag assays to examine the applicability of
these assays in tumor models. We chose N87 since this cell line
shows detectable levels of both HER2 and HER3 and is known to
be HER2-driven [35]. Tumor fragments from N87 were
implanted into mice to generate the xenografts. We monitored
total protein (Figure S10), protein-complexes and phosphoproteins
(Figure 6) using VeraTag FFPE assays.
Relative stabilities of protein-complexes and
phosphoproteins
A major consideration in using solid tumor patient samples for
the detection and measurement of prognostic or predictive
biomarkers is the stability of the marker pre- and post-fixation.
In particular, protein phosphorylation is sensitive to the time
between excision of the patient’s tumor and fixation in formalin.
To investigate the stability of selected targets and the potential loss
of receptor phosphorylation due to delayed fixation in a model
system, we left the excised N87 xenografts at room temperature for
different times up to 2 h post-surgery, before either fixing them in
NBF for making FFPE blocks or preparing lysate samples. We
performed the HER23D, HER3P and HER3PI3K assays on these
samples and found no significant degradation of either HER23D
or HER3PI3K at any measured time point up to 2 h of delayed
fixation. However, we saw evidence of the degradation of HER3P
after 2 h (Figure 6), while total protein remained constant (Figure
S10A–B). There is no statistically significant difference in either
the HER23D or the HER3PI3K measurements between any of
the five groups of mice (p-values .0.5 and .0.2 respectively). The
HER3P measurements, however, drop measurably for groups
three, four and five. The difference in the HER3P measurements
of group one and group five reached statistical significance (p-
value=0.012). As with cell-line data, the data from the FFPE
assays correlated well with co-immunoprecipitation/Western Blot
from the same tumors.
Discussion
Despite the success of targeted therapies for the treatment of
solid tumors, drug resistance is still a major issue and concern.
While many different targeted therapy resistance mechanisms
have been advanced based on in vitro cell line models, there has
been very little study to ascertain whether these mechanisms are
significant in the more complex biological setting of a patient’s
tumor. What are clearly lacking at this present time are
appropriate techniques for the robust examination of activated
signaling pathways in FFPE tumor sections. Approaches to
accurately and reproducibly measure multiple nodes in a pathway
should allow identification of a tumor’s oncogenic pathway
addiction as well as highlight potential activated resistance
pathways that may result in poor, or limited, response to therapy.
We have developed a technology platform that permits
quantitative measurements of proteins, protein complexes and
phosphorylation in FFPE tumors. In this study, we described the
use of a dual antibody-based, proximity-driven assay for the
detection and quantitation of receptor dimers and protein
complexes in the HER3/PI3K/Akt pathway. Our results indicate
we can measure molecular perturbations at key nodes along this
pathway either as a function of ligand stimulation, HER2 over-
expression or inhibitor action in a panel of breast cancer cell lines.
In matched FFPE sample and cell lysate studies, there is good
qualitative agreement between the VeraTag assay and data
obtained from traditional Western blotting or co-immunoprecip-
itation experiments. In addition, we generated a comparable set of
data with a cell lysate version of the VeraTag assay (described in
Text S1 and Figure S7), which retains the quantitative
HER3/PI3K Pathway Profiling in Breast Tumors
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validation of the FFPE data. In breast tumors, we confirmed that
this panel of analytes can be reproducibly measured at levels above
assay background and over a dynamic range consistent with
expectation based on cell line models. The positive correlations
between HER23D, HER3PI3K and HER3P (Table 1) are
expected, as a result of the known signaling in the pathway.
Interestingly, the dimerization of HER2 with HER3 appears to be
a strong function of HER2 over-expression [36] in this set of
tumors, and is a strong indicator of the activation of this pathway,
and is likely to be a useful biomarker. The abundance of ligand-
independent HER23D is consistent with low HRG expression in
high HER2 breast cancer cell lines and tumors [34]. The
agreement between HER2T and HER3P measurements is also
understandable, since HER2 preferentially phosphorylates HER3
[37] and HER3 receptor is functionally involved in the biology of
HER2-positive breast tumors and now represents a new molecular
target of therapy [38]. HER23D and HER3PI3K measurements
could prove to be useful alternatives to a HER3P biomarker, given
their strong covariance.
Figure 3. VeraTag assays to monitor signaling pathways in breast tumors. FFPE sections from HER2-positive tumors were subjected to
HER23D, HER3P and HER3PI3K VeraTag assays (A). Cell-line controls for each assay were used as indicated on the x-axis. Underscore H (_H) indicates
cells were treated with HRG. The normalized RPA values after correction for ITC signal was plotted on the y-axis. (B) Correlations between HER23D,
HER3P and HER3PI3K signal from VeraTag assays. (C) Correlations between HER2T and markers of HER3 activation (HER23D, HER3P and HER3PI3K)
from VeraTag assays.
doi:10.1371/journal.pone.0016443.g003
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a marker of pathway activation although the stability of this
measurement can be adversely affected by a variety of factors [4].
We measured HER3 phosphorylation in a significant number of
well-preserved tumors in this study; however, protocols to preserve
target integrity in tumors are not always applied uniformly,
especially in a busy pathology laboratory. Therefore, phosphor-
ylation may not be a reliable indicator of pathway signaling in all
patient cohorts. In cell lines stimulated with ligand, we observed
strong covariance between three key markers of activation,
namely, HER3P, HER3PI3K and pAkt. However, in xenograft
experiments where fixation of the tumor was intentionally delayed
after removal from the animal, we observed a significant
degradation of HER3 phosphorylation for the longest time point,
while the HER3PI3K complex signal and the HER23D signals
were unaffected. We believe that measurement of the HER3PI3K
complex could provide a more robust read-out of pathway
activation than, for example, HER3 or Akt phosphorylation. It is
known that SH2 domains can prevent tyrosine dephosphorylation
in vitro [39], which could explain the increased stability of the
HER3PI3K complex since the p85 subunit utilizes two SH2
domains to bind to phosphorylated HER3.
We chose three clinically validated HER2 targeting drugs
reviewed in [40] to demonstrate that the results of therapeutic
Table 1. Correlations of HER3/PI3K pathway analytes in
breast tumors.
Correlations n# r
2 **p-value
HER2T and HER3T 27 .065 .1993
HER2T and HER23D 25 .670 ,0.0001
HER2T and HER3P 18 .254 .0329
HER2T and HER3PI3K 22 .266 .0140
HER3T and HER23D 25 .129 .0776
HER3T and HER3P 18 .093 .2195
HER3T and HER3PI3K 22 .158 .0671
HER23D and HER3P 17 .445 .0035
HER23D and HER3PI3K 21 .246 .0222
HER3P and HER3PI3K 17 .617 .0002
*The normalized RPA values after correction for ITC signal was used in the
analysis.
# The number of tumors (n) eligible for each analysis.
1The correlation coefficients (Pearson r) were calculated and expressed as r
2.
**Two-tailed p-value was determined and the correlation was considered
statistically significant when p,0.03, shown in bold.
doi:10.1371/journal.pone.0016443.t001
Figure 4. Effects of trastuzumab, 2C4 and lapatinib on molecular markers under HRG-stimulated conditions. T47D cells were exposed to
trastuzumab, 2C4, lapatinib or left untreated prior to treatment with heregulin. VeraTag assays to measure (A) HER23D, (B) HER3P, (C) p/t-Akt and (D) HER3PI3K
were performed on FFPE sections prepared from these cells. The normalized RPA values are plotted on the y-axis. The treatments are indicated on the x-axis.
doi:10.1371/journal.pone.0016443.g004
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with VeraTag FFPE assays. 2C4 is the first of a new class of agents
known as HER dimerization inhibitors, which act by binding to
HER2, thus preventing dimerization with other HER partners.
Trastuzumab (Herceptin) differs from 2C4 in that it is active in
high HER2 expressing tumors. Lapatinib is a type I tyrosine kinase
inhibitor (TKI) with reactivities towards both EGFR and HER2.
Since HER2 is a key determinant of the levels of the HER23
heterodimers and other downstream targets measured in the
HER3/PI3K pathway in the breast cancer cell lines we studied,
therapeutic inhibition of HER2 should be reflected in the
inhibition of this pathway. Response, as measured by pathway
activation, was attenuated by the HER-targeted therapies to
different degrees, was cell line specific and was dependent on the
mode of pathway activation. Basally activated BT474 was
inhibited by trastuzumab and lapatinib, but not by 2C4. Although,
under the experimental conditions used, we did not observe
inhibition of ligand-independent HER23 dimerization in BT474
either by co-immunoprecipitation/Western blotting or by Ver-
aTag assays, there is evidence of pathway inhibition by
trastuzumab and especially lapatinib, as pAkt is attenuated. The
lack of a measurable effect of trastuzumab on HER23D in BT474
cells was unexpected [13] and is being further investigated.
In ligand activated T474D, 2C4 shows the expected inhibition
of HER23D, HER3P and HER3PI3K, consistent with the
disruption of HER heterodimers. By contrast, trastuzumab has
no effect on these analytes. Lapatinib, however, shows a
statistically significant inhibition of HER23D that is unexpected
based on known mechanisms of action of TKIs. A possible
explanation is that the structural flexibility and stability of inactive-
like conformation of HER2 could potentiate lapatinib binding, in
a manner seen with lapatinib binding to EGFR [41]. This in turn
could lead to the lack of active HER2 available to form HER23D.
Surprisingly, for lapatinib and 2C4, upstream pathway inhibition
was not accompanied by a decrease in the phosphorylation of Akt.
The T47D cell line is known to contain a strongly activating
mutation in the kinase domain of PI3-kinase (H1047R), which
signals through Akt [42]. This mutation upregulates the
phospholipid kinase activity of the protein independent of Ras
interaction. Our data indicates that there is residual HER3
phosphorylation at the drug concentrations used under conditions
of HRG stimulation, and we speculate that this may be sufficient,
Figure 5. Effects of trastuzumab, 2C4 and lapatinib on molecular markers of basally activated breast cancer cells. BT474 cells were
exposed to trastuzumab, 2C4, lapatinib or left untreated. VeraTag assays to measure (A) HER23D, (B) HER3P, (C) p/t-Akt and (D) HER3PI3K were
performed on FFPE sections prepared from these cells. The normalized RPA values are plotted on the y-axis. The treatments are indicated on the x-axis.
doi:10.1371/journal.pone.0016443.g005
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maintain Akt phosphorylation.
In conclusion, we demonstrate the capability of VeraTag
assays to quantitatively measure molecular changes in the
HER3/PI3K/Akt pathway in both breast cancer cell lines and
tumors. Multiple measurements in the pathway, including those
that are less dependent on the tissue preservation methodology,
should give a more complete picture of pathway status and have
greater utility as prognostic or predictive biomarkers. This study
provides validation of previous work and extends our knowledge
of HER3 complexes in tumors and their responses to selected
HER2-targeted therapies. Although the data presented here
pertains to the HER family, this assay system is readily adaptable
to other protein families for which antibodies or other recognition
elements are available due to the universal nature of the assay.
Supporting Information
Figure S1 Principle of the VeraTag assay. Antibodies are
added to the FFPE tissue section where they bind to their specific
targets. One antibody is labeled with biotin; the other antibody is
labeled with a VeraTag. Following the addition of SA-MB, a
reactive singlet oxygen species is generated in response to
photoactivation and the VeraTag is cleaved from the bound
antibody; only VeraTags in proximity to the cleavage agent are
released. The cleaved VeraTags from each sample are collected in
a single well of a 96-well plate and read on a conventional ABI
3100 CE instrument. The resulting electropherogram is analyzed
by the VeraTag Informer software, which identifies the VeraTag
peak based on its mobility. Each target measured in the assay is
assigned to a unique VeraTag.
(TIF)
Figure S2 Work-flow of the VeraTag assay. FFPE slides
are dewaxed and hydrated following established IHC protocols
(A). Antigen retrieval is done in a pressure cooker (B). Following
cooling and addition of blocking buffer, the antibody mix is added
to each section (C). The slides are washed, SA-MB added and the
VeraTag is cleaved upon illumination (D). The released VeraTag
is separated on a CE machine (E) and analyzed using informer
software (F).
(TIF)
Figure S3 Determination of antibody cross-reactivity by
immunohistochemistry. FFPE sections from BT474, HEK
293, HEK 293-HER3 (HEK 293 transfected with HER3) cell lines
were immunostained with the indicated antibodies following
standard IHC protocols on Ventana Discovery autostainer as
described in the Materials and Methods. All images are at 10x
magnification. (A) Strong-intensity HER3 staining with B9A11. (B)
Negative control Mo IgG. (C) Strong-intensity HER3 staining
with SC-285. (D, E) Negative control cell lines for HER3. (F)
Strong HER2 staining intensity with HER2 antibody Ab-8.
(TIF)
Figure S4 Isotype control and Alkaline Phosphatase
experiments. A–C: The indicated cell lines were serum-starved
overnight and were either treated with 60 nM HRG (_H) in media
for 10 min or left untreated. MDA-MB-231 and NIH-3T3 cells
Figure 6. VeraTag assays to monitor signaling pathways in N87 xenograft tumors. HER3PI3K (A), HER23D (B) and HER3P (C) VeraTag assays
were performed on tumors obtained from the five groups of mice (G1–G5). The normalized RPA values are plotted on the y-axis. The error bars
denote the standard error of the mean (SEM) from measurements of the three mice per time point. Equal amounts of total protein from the tumors of
the five groups of mice (three mice per group) were subjected to immunoprecipitation using anti-HER3 antibody (D). SDS-PAGE followed by western
blotting was performed to detect HER23D, HER3P and HER3PI3K as described in Material and Methods.
doi:10.1371/journal.pone.0016443.g006
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either subjected to the VeraTag FFPE HER23D, HER3PI3K and
HER3P assays or the corresponding ITC assays where the biotin-
labeled HER3 antibody is replaced with biotin-labeled mouse
IgG1k. The normalized RPA values are plotted on the y-axis.
Signal from ITC experiment is denoted by the solid bar and assay
signal by hatch-marked bars. D–F: FFPE sections for each cell line
were processed as described in the Materials and Methods and
then treated with alkaline phosphatase overnight or left untreated
before resuming with the rest of the VeraTag assays. HER23D,
HER3P and HER3PI3K assays were performed on the FFPE
sections from the panel of 10 breast cancer cell lines with and
without HRG stimulation. The normalized RPA values are plotted
on the y-axis. Signal from AP treatment is denoted by the solid bar
and assay signal by hatch-marked bars.
(TIF)
Figure S5 Demonstration of precision of the HER23D,
HER3P and HER3PI3K assays. A–C: Serial FFPE sections for
each cell line were run in the HER23D (A), HER3PI3K(B) and
HER3P (C) assays on the same day (eight replicates), as indicated,
and the normalized RPA values are plotted on the y-axis.
(TIF)
Figure S6 Analysis of breast cancer cell line panel. A–B:
Total HER2 (top panel) and total HER3 (bottom panel) FFPE
assays. The indicated cell lines were serum-starved overnight and
were either treated with 60 nM HRG in media for 10 min or left
untreated. MDA-MB-231 and NIH-3T3 cells were used without
starvation or treatment (refed: RF). FFPE blocks were prepared as
described in Materials and Methods. FFPE sections cut from the
blocks were used to perform VeraTag assays. Data from the assays
were analyzed, and the results are plotted in the graphs. The
normalized RPA values are plotted on the y-axis. HRG-stimulated
signal is denoted by the solid bars and unstimulated signal by
hatch-marked bars. C–D: HER2-HER3 heterodimer, phospho-
HER3, HER3-PI3K, phospho-Akt analysis of breast cancer cell
lines. C-Top panel: 50 mg portion of protein extract from the
indicated cell lysates were fractionated by SDS-1% PAGE and
transferred to a PVDF membrane. The membrane was immuno-
blotted with HER2, HER3, actin, p-serine 473 Akt, Akt and p85
antibodies. b-Actin is shown for loading control. D-Bottom
panel: mg portion of protein extract from the indicated cell lysate
was immunoprecipitated (IP) with anti-HER3 antibody. Immu-
noprecipitates were fractionated by SDS-1% PAGE and trans-
ferred to a PVDF membrane. The membrane was immunoblotted
with HER2, phosphotyrosine and p85 antibodies.
(TIF)
Figure S7 A–D: Total HER3, HER23D, HER3P and
HER3PI3K analysis of breast cancer cell lines by
VeraTag lysate assays. The indicated cell lines were serum-
starved overnight and were either treated with 60 nM heregulin in
media for 10 min or left untreated. MDA-MB-231 and NIH-3T3
cells were used without starvation or treatment. Cell lysates were
prepared in lysis buffer as described in Materials and Methods and
protein lysates were quantified. The lysates were subjected to
VeraTag lysate assays. Data from the assays were analyzed and the
results are plotted in the graphs. The RPA values per mg of protein
are plotted on the y-axis. HRG stimulated signal is denoted by the
solid bars and unstimulated signal by hatch-marked bars.
(TIF)
Figure S8 Effects of trastuzumab, 2C4 and lapatinib
on molecular markers under HRG-stimulated condi-
tions. A: 300 mg portion of protein extract from the drug treated
T47D cell lysates were immunoprecipitated (IP) with biotin-
labeled anti-HER3 antibody. Immunoprecipitates were fraction-
ated by SDS-1% PAGE and transferred to a PVDF membrane.
The membrane was immunoblotted with anti-HER2, anti-
phosphotyrosine and p85 antibodies. Each lane contains equal
amounts of immunoprecipitate. Western Blot of the indicated
T47D lysates treated with drugs was performed with phospho-Akt
and total Akt antibodies after SDS-PAGE and transfer to a PVDF
membrane of 50 mg lysate. B: VeraTag Akt lysate assay was
performed on the indicated T47D lysates treated with drugs
(80 mg each). The data is presented as the ratio of phospho-Akt to
total Akt.
(TIF)
Figure S9 Effects of trastuzumab, 2C4 and lapatinib on
molecular markers of basally activated breast cancer
cells. A: 300 mg portion of protein extract from the drug treated
BT474 cell lysates were immunoprecipitated (IP) with biotin-
labeled anti-HER3 antibody. Immunoprecipitates were fraction-
ated by SDS-1% PAGE and transferred to a PVDF membrane.
The membrane was immunoblotted with anti-HER2, anti-
phosphotyrosine and p85 antibodies. Each lane contains equal
amounts of immunoprecipitate. Western Blot of the indicated
BT474 lysates treated with drugs was performed with phospho-Akt
and total Akt antibodies after SDS-PAGE and transfer to a PVDF
membrane of 50 mg lysate. B: VeraTag Akt lysate assay was
performed on the indicated BT474 lysates treated with drugs ( mg
each). The data is presented as the ratio of phospho-Akt to total
Akt.
(TIF)
Figure S10 A–B: HER2 and HER3 levels are not affected
by dephosphorylation upon delayed fixation in xeno-
graft. Tumors sections from the five groups of mice were
subjected to the VeraTag FFPE HER2T and HER3T assays. The
normalized RPA values are plotted on the y-axis.
(TIF)
Text S1 Details of the VeraTag assay technology,
protocols and assay characterization.
(DOC)
Table S1 Flow cytometric analysis of HER2 and HER3
receptors are reported as number of receptors per cell
for all the cell lines used in the study.
(DOC)
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